¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low renin hypertension"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® hypertension ÇÑ±Û °íÇ÷¾Ð
¼³¸í   
  µ¿¸ÆÀÇ Ç÷¾ÐÀÌ ³ôÀº °Í. ÀϹÝÀûÀ¸·Î ¸»Çϴ °íÇ÷¾ÐÀº ÀÌ µ¿¸Æ¼º °íÇ÷¾ÐÀ» ¸»ÇÑ´Ù. Ç÷¾ÐÀ̶õ Ç÷°ü¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϴ °ÍÀ¸·Î ´ë°³ Æ¯ÀÌÇÑ ¼³¸íÀÌ ¾øÀ¸¸é µ¿¸ÆÀÇ ¾Ð·ÂÀ» ¸»ÇÑ´Ù. Ç÷¾Ð¿¡´Â ¼öÃà±âÇ÷¾Ð°ú À̿ϱâÇ÷¾ÐÀÌ ÀÖ´Ù. ¼öÃà±âÇ÷¾ÐÀ̶õ ½ÉÀåÀÌ ¼öÃàÇÒ ¶§ÀÇ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»Çϰí À̿ϱâ Ç÷¾ÐÀ̶õ ½ÉÀåÀÌ ÀÌ¿ÏÇÒ °æ¿ì¿¡ µ¿¸Æ¿¡ °É¸®´Â ¾Ð·ÂÀ» ¸»ÇÑ´Ù. ´ç¿¬È÷ ¼öÃà±â Ç÷¾ÐÀÌ À̿ϱâ Ç÷¾Ðº¸´Ù ³ô´Ù. Ç÷¾ÐÀ» ¸»ÇÒ ¶§¿¡ 120/80À̶ó°í Àû´Â °ÍÀÇ ¾ÕÀÇ °ÍÀº ¼öÃà±â Ç÷¾ÐÀ» ÀǹÌÇÏ°í µÚ¿¡ Àû´Â 80Àº À̿ϱâ Ç÷¾ÐÀ» ÀǹÌÇÑ´Ù.
  
  °íÇ÷¾ÐÀº ÁַΠÀ̿ϱâÀÇ Ç÷¾ÐÀ» ±âÁØÀ¸·Î Á¤ÇÑ´Ù. ¿©·¯ °¡Áö ±âÁØÀÌ ÀÖÀ¸³ª À̿ϱâ Ç÷¾ÐÀÌ 90mmHgÀÌ»óÀΠ°æ¿ì¸¦ ¸»ÇÑ´Ù. °íÇ÷¾Ð ÀÚü¿¡ ÀÇÇÑ Áõ»óÀº º°·Î ¾ø´Ù. ´Ù¸¸ °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´Áõ°ú µ¿¸Æ°æÈ­ÀÇ ÃËÁø¿¡ ÀÇÇØ º´¹ßÇϴ Áúȯ¿¡ ÀÇÇÏ¿© Áõ»óÀÌ »ý±ä´Ù. °íÇ÷¾Ð¿¡ ÀÇÇÑ ÇÕº´ÁõÀº ´ë°³ Ç÷°ü¿¡ °É¸®´Â °úµµÇÑ ¾Ð·ÂÀ¸·Î ÀÎÇÑ Ç÷°üÀÇ ¼Õ»óÀÌ Áß¿äÇÑ ¿øÀÎÀÌ´Ù.
  
  °íÇ÷¾ÐÀº µ¿¸Æ°æÈ­ÀÇ ÁÖ¿ä À¯¹ßÀÎÀÚ ÁßÀÇ ÇϳªÀÌ´Ù. µ¿¸Æ°æÈ­´Â µ¿¸ÆÀÇ º®ÀÌ µÎÅÍ¿öÁö°í µ¿¸ÆÀ̠ź·ÂÀ» ÀÒ¾î¹ö¸®´Â ÁúȯÀÌ´Ù. ¾î¶² µ¿¸ÆÀÌ µ¿¸Æ°æÈ­¿¡ °É¸®¸é ÀÌ µ¿¸ÆÀº µÎÅÍ¿öÁø Ç÷°üº®¿¡ ÀÇÇØ¼­ ³»°æÀÌ ÀÛ¾ÆÁö°Ô µÈ´Ù. ÀÌ·¸°Ô µÇ¸é ±× µ¿¸ÆÀ¸·ÎºÎÅÍ Ç÷¾×À» °ø±Þ¹Þ´ø Àå±â´Â Ç÷¾×À» Àû°Ô °ø±Þ¹Þ°Ô µÇ°í ±× Á¤µµ°¡ ½ÉÇϰԠµÇ¸é ±× Àå±â´Â °á±¹ ¼Õ»óÀ» ÀÔ°Ô µÈ´Ù. µ¿¸Æ°æÈ­·Î ÀÎÇÑ Áúº´ÀÇ ´ëÇ¥ÀûÀΠ¿¹´Â ½ÉÀåÀÇ ±ÙÀ°¿¡ Ç÷¾×À» °ø±ÞÇϴ ½ÉÀ嵿¸Æ¿¡ µ¿¸Æ°æÈ­ÀÇ º¯È­°¡ ¿À´Â ½ÉÀ嵿¸Æº´ÀÌ´Ù.
  
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ ¾²À̴ ¾à¹°Àº ´ÙÀ½°ú °°Àº °ÍÀÌ ÀÖ´Ù.
  
  -ÀÌ´¢Á¦-ÄáÆÏ¿¡¼­ ¼öºÐ°ú ÀüÇØÁúÀÇ ¹èÃâÀ» ÃËÁø½Ã۴ ¾à¹°. Ã¼³»ÀÇ ¼öºÐÀÇ ¾çÀ» °¨¼Ò½ÃÄѼ­ Ç÷¾×ÀÇ È帣´Â ¾çÀ» Àû°ÔÇÏ°í ¶Ç Ç÷°üÁÖÀ§ Á¶Á÷ÀÇ ¼öºÐÀÇ °¨¼Ò·Î Ç÷°üÀ» È®Àå½Ã۴ ¿ªÇÒ(Ç÷°üÀÌ ÀÖ°í ±× Ç÷°üÀ» ½×°í Àִ Á¶Á÷¿¡ ¼öºÐÀÌ Â÷ ÀÖÀ¸¸é ±× Á¶Á÷ÀÌ Ç÷°üÀ» ´­·¯¼­ Ç÷°üÀÌ È®ÀåÇϴ °ÍÀ» ¹æÇØÇÑ´Ù)·Î Ç÷¾ÐÀ» °¨¼Ò½ÃŲ´Ù.
  
  -Ä®½·-Åë·ÎÂ÷´ÜÁ¦£­¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Áï Ç÷°üÀÇ ¼öÃà¿¡ °ü¿©Çϴ Ç÷°üµµ ¿ª½Ã ¼öÃàÀ» À§Çؼ­´Â Ä®½·ÀÌ ÇÊ¿äÇÏ´Ù. Ä®½·-Åë·ÎÂ÷´ÜÁ¦´Â ±ÙÀ°¼¼Æ÷ ¼ÓÀ¸·Î Ä®½·ÀÌ µé¾î°¡´Â °ÍÀ» ¹æÁöÇØ¼­ Ç÷°ü±ÙÀ°ÀÇ ¼öÃàÀ» ¹æÇØÇϰí À̷ΠÀÎÇØ¼­ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÑ´Ù.
  
  -¾ËÆÄÂ÷´ÜÁ¦, º£Å¸Â÷´ÜÁ¦-Ç÷°üÀº ÀÚÀ²½Å°æ°èÀÇ Áö¹è¸¦ ¹Þ´Â´Ù. ±×Áß¿¡¼­µµ Ç÷°üÀº ±³°¨½Å°æÀÇ ¿µÇâ¿¡ ÀÇÇØ¼­ ¼öÃà°ú ÀÌ¿ÏÀ» ÇÑ´Ù. ±³°¨½Å°æÀÇ ÀÛ¿ëÀº ±× ¼ö¿ëü¿¡ µû¶ó ´Þ¶óÁø´Ù. ±³°¨½Å°æÀÇ ¼ö¿ëüÀÇ Á¾·ù¿¡´Â ¾ËÆÄ¼ö¿ëü¿Í º£Å¸¼ö¿ëü°¡ ÀÖ´Ù. Ç÷°üÀ» Áö¹èÇϰí Àִ ±³°¨½Å°æ¿¡¼­ ¾ËÆÄ¼ö¿ëü´Â Ç÷°üÀÇ ¼öÃàÀ» ÀÏÀ¸Å°°í º£Å¸¼ö¿ëü´Â Ç÷°üÀÇ È®ÀåÀ» ÀÏÀ¸Å²´Ù. ±×·¯¹Ç·Î ¾ËÆÄ¼ö¿ëüÀÇ ÀÛ¿ëÀ» ¸·´Â °æ¿ì¿¡ Ç÷°üÀÇ È®ÀåÀ» À¯µµÇÒ ¼ö ÀÖ°í º£Å¸-¼ö¿ëüÀÇ ÀÛ¿ëÀ» Ç×Áø½Ãų °æ¿ì¿¡ ¿ª½Ã Ç÷°üÀÇ È®Á¤À» À¯µµÇÒ ¼ö ÀÖ´Ù.
¿µ¹® renal hypertension ÇÑ±Û ÄáÆÏ¼º°íÇ÷¾Ð
¼³¸í   
  ÄáÆÏ½ÇÁúÀÇ º´º¯À¸·Î ÀÎÇØ ¾ß±âµÈ °íÇ÷¾Ð. ÄáÆÏÀÇ ´ëÇ¥Àû ±â´ÉÀº ³ëÆó¹° ¹× ¼öºÐÀÇ ¹è¼³ÀÌ´Ù. ±×·±µ¥ ÀÌ·¯ÇÑ ÄáÆÏ±â´É¿¡ ÀÌ»óÀÌ »ý°åÀ» °æ¿ì Ã¼³»¿¡ °úÀ×¼öºÐÀÇ ÃàÀûÀÌ ¹ß»ýÇϰԠµÈ´Ù. À̿Ͱ°Àº °úÀ×¼öºÐÀÇ ÃàÀûÀº Ç÷°ü³» Á¤¼ö¾ÐÀ» »ó½Â½ÃÄÑ °íÇ÷¾ÐÀ» À¯¹ßÇϰԠµÈ´Ù. Ä¡·á´Â ¿øÀΠÄáÆÏº´ÀÇ ±³Á¤À̸ç ÀÌÀ¯¸¦ ¸ð¸£´Â ¿ø¹ß°íÇ÷¾Ð°ú ´Þ¸® ÄáÆÏ¼º°íÇ÷¾ÐÀÇ °æ¿ì¿¡´Â ¿øÀΠÄáÆÏº´ÀÌ ±³Á¤µÇ¸é °íÇ÷¾Ðµµ »ç¶óÁö°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renin
    ·¹´Ñ
  • renin substrate
    ·¹´Ñ±âÁú
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ØÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ׷аèÅë
  • renin-producing
    ·¹´Ñ»ý¼º-
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å¼º°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • essential hypertension
    º»Å°íÇ÷¾Ð
  • hypertension
    1. °íÇ÷¾Ð 2. °íÇ÷¾ÐÁõ 3. °í¾Ð
  • intracranial hypertension
    µÎ°³³»¾Ð»ó½Â
  • juvenile hypertension
    ¼Ò¾Æ°íÇ÷¾Ð
  • labile hypertension
    ºÒ¾ÈÁ¤°íÇ÷¾Ð
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renin
    ·¹´Ñ
  • renin substrate
    ·¹´Ñ±âÁú
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç, ·¹´ÑºÐºñ»ç±¸Ã¼¿·Á¾¾ç
  • low fever
    ¹Ì¿­
  • low risk group
    ÀúÀ§Ç豺
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁöÁú´Ü¹é
  • low potency
    ÀúÈ¿´É, Àú¿ª°¡, ÀúÀáÀç·Â
  • low signal
    ¾àÇѽÅÈ£, Àú½ÅÈ£
  • hypertension
    °íÇ÷¾Ð
  • ocular hypertension
    °í¾È¾ÐÁõ
  • portal hypertension
    ¹®¸Æ°íÇ÷¾Ð
  • pregnancy-induced hypertension
    ÀӽŰíÇ÷¾Ð
  • pulmonary hypertension
    Æóµ¿¸Æ°íÇ÷¾Ð, ÇãÆÄ°íÇ÷¾Ð
  • renovascular hypertension
    ÄáÆÏÇ÷°ü°íÇ÷¾Ð, ½ÅÀåÇ÷°ü°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • low renin hypertension
    Àú·¹´Ñ°íÇ÷¾Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renin
    ·¹´Ñ
  • renin-producing
    ·¹´Ñ»ý¼º-
  • renin substrate
    ·¹´Ñ±âÁú
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñÅ丮°çÁ¾¾ç
  • accelerated hypertension
    °¡¼Ó°íÇ÷¾Ð
  • adrenal hypertension
    ºÎ½Å°íÇ÷¾Ð
  • borderline hypertension
    °æ°è°íÇ÷¾Ð
  • diastolic hypertension
    È®Àå±â°íÇ÷¾Ð
  • essential hypertension
    º»Å°íÇ÷¾Ð
  • hypertension
    °íÇ÷¾Ð
  • intracranial hypertension
    µÎ°³³»¾Ð»ó½Â
  • juvenile hypertension
    ¼Ò¾Æ°íÇ÷¾Ð
  • labile hypertension
    (¢¡borderline hypertension) °æ°è°íÇ÷¾Ð
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • ocular hypertension
    °í¾È¾ÐÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Castellani-Low symptom
    Ä«½ºÅÚ¶ó´Ï-·Î¿ìÁõ»ó.
  • LDL = low density lipoprotein
    Àú¹ÐµµÁö´Ü¹é(î¸ÚËÓøò·Ó±ÛÜ)
  • VLDL => very low density lipoprotein
    ÃÊÀú¹ÐµµÁö ´Ü¹éÁú
  • frequency deafness, low
    ÀúÁ֯ijó, ÀúÁÖÆÄ±Í¸ÔÀ½
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • plasma renin activity
    Ç÷Àå·¹´ÑȰ¼ºµµ<--Ȱµ¿µµ>
  • renin
    ·¹´Ñ.
  • renin angiotensin aldosterone pressor
    ·¹´Ñ¾ÈÁö¿ÀÅٽž˵µ½ºÅ׷н ¾Ð°è(¡­ã°äâ
  • renin angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅٽŰè(¡­Í§).
  • renin substrate
    ·¹´Ñ±âÁú.
  • renin-angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅÙ½Åü°è
  • renin-angiotensin system
    ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè(¡­Ìõ)
  • renin-angiotensin-aldosterone axis
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·ÐÃà<--°è>
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ðü°è
  • renin-producing
    ·¹´Ñ»ý¼º(¡­ßæà÷)ÀÇ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • low renin essential hypertension
    Àú·¹´Ñ¼º º»Å¼º °íÇ÷¾Ð(­àõÜâ÷¾àõÍÔúì äâ).
  • kidney,renin-producing juxtaglomerular cell tumor
    ·¹´ÑºÐºñ¹æ»ç±¸Ã¼¼¼Æ÷Á¾(¡­ÝÂÝôÛ¨Þêϳô÷á¬øàðþ)
  • plasma renin activity
    Ç÷Àå·¹´ÑȰ¼ºµµ<--Ȱµ¿µµ>
  • renin
    ·¹´Ñ.
  • renin angiotensin aldosterone pressor
    ·¹´Ñ¾ÈÁö¿ÀÅٽž˵µ½ºÅ׷н ¾Ð°è(¡­ã°äâ
  • renin angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅٽŰè(¡­Í§).
  • renin substrate
    ·¹´Ñ±âÁú.
  • renin-angiotensin system
    ·¹´Ñ¾ÈÁö¿ÀÅÙ½Åü°è
  • renin-angiotensin system
    ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè(¡­Ìõ)
  • renin-angiotensin-aldosterone axis
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·ÐÃà<--°è>
  • renin-angiotensin-aldosterone system
    ·¹´Ñ-¾ÈÁö¿ÀÅÙ½Å-¾Ëµµ½ºÅ×·Ðü°è
  • renin-producing
    ·¹´Ñ»ý¼º(¡­ßæà÷)ÀÇ
  • renin-secreting juxtaglomerular tumor
    ·¹´ÑºÐºñ¼º¹æ»ç±¸Ã¼Á¾¾ç
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð.
  • adrenal hypertension
    ºÎ½Å¼º °íÇ÷¾ÐÁõ(¡­ÍÔúìäâñø).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renal hypertension
    ½Å°íÇ÷¾Ð(ãìÍÔúìäâ)
  • renin
    ·¹´Ñ 1995. 12. 29.
  • renin substrate
    ·¹´Ñ ±âÁú(Ðñòõ)
  • low-angle x-ray diffraction
    ¼Ò°¢(á³ÊÇ) X-¼±È¸Àý(àÊüÞï¹)
  • low background counter
    ³·Àº¹ÙÅÁ °è¼ö±â(ͪâ¦Ðï)
  • low-copy number
    Àú(î¸)Ä«ÇǼö(â¦)
  • low-density fraction
    Àú¹ÐµµºÐȹ(î¸ÚËÓøÝÂüñ)
  • low-density lipoprotein
    Àú¹Ðµµ Áö´Ü¹éÁú(î¸ÚËÓøò·Ó±ÛÜòõ)
  • low-energy compound
    Àú(î¸)¿¡³ÊÁöÈ­ÇÕ¹°(ûùùêÚª)
  • low-energy electron diffraction
    Àú(î¸)¿¡³ÊÁö ÀüÀÚȸÀý(ï³í­üÞï¹)
  • low-energy ion scattering
    Àú(î¸)¿¡³ÊÁö À̿ºлê(ÝÂߤ)
  • low-energy phophate acceptor
    Àú(î¸)¿¡³ÊÁö Àλê¼ö³³Ã¼(×òß«áôÒ¡ô÷)
  • low-frequency transduction
    Àúºóµµ ÇüÁúµµÀÔ(î¸ÞºÓøû¡òõÓôìý)
  • low-level promoter
    ÀúÀ§(î¸êÈ) ÇÁ·Î¸ðÅÍ
  • low-lipid lipoprotein
    ÀúÁöÁú Áö´Ü¹éÁú(î¸ò·òõò·Ó±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renin
    ·¹´Ñ
  • essential hypertension
    º»Å¼º°íÇ÷¾Ð
  • hypertension
    °íÇ÷¾ÐÁõ, ±äÀåÇ×ÁøÁõ
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ
  • portal hypertension
    ¹®¸Æ¾ÐÇ×ÁøÁõ, ¹®¸Æ°íÇ÷¾Ð
  • primary hypertension
    ¿ø¹ß(¼º)°íÇ÷¾ÐÁõ
  • renal hypertension
    ½Å¼º°íÇ÷¾Ð
  • renovascular hypertension
    ½ÅÇ÷°ü¼º°íÇ÷¾Ð
  • splenoportal hypertension
    ºñ¹®¸Æ¼º°íÇ÷¾ÐÁõ
  • fast Low Angle Shot [=FLASH]
    °í¼ÓÀú°¢¿µ»óȹµæ
  • low attenuation
    ³·Àº °¨¾à
  • low back pain
    ¿äÅë
  • low echo area
    Àú¿¡ÄÚ±¸¿ª
  • low field MR scanner
    ÀúÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • low intensity void in proton flow
    ¾ç¼ºÀÚÈ帧ÀÇ Àú°­µµ¼Ò½Ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LREH low renin essential hypertension
LP labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar...
HREH high-renin essential hypertension
NREH normal renin essential hypertension
REH renin essential hypertension
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LREH Low-renin essential hypertension
STOP Hypertension Swedish Trial in Old Patients with Hypertension
AR Active renin
PRC Plasma Renin Concentration
PRS Plasma Renin Substrate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • renin
    ·¹´Ñ
  • low biscuit stage µµÀç ÀÔÀÚ°¡ ¼­·Î ÀÀÁýµÇ³ª ´Ù°ø¼ºÀ̸ç, ºÎ¼­Áö±â ½¬¿î »óÅÂ.

    low blood pressure

    ÀúÇ÷¾Ð
    Ç÷¾Ð°è·Î Àü¿Ï µ¿¸ÆÀÇ Ç÷¾ÐÀ» ÃøÁ¤ÇÏ¿´À» ¶§ Ç÷¾ÐÀÌ Á¤»óº¸´Ù ³·Àº °æ¿ìÀÇ ÃÑĪ. Á¤»ó °ªÀº ¿¬·É, ¼º¿¡ µû¶ó ´Ù¸£Áö¸¸, ´ë°³ ÃÖ°í Ç÷¾ÐÀÌ 100 mmHg ÀÌÇÏÀ̸é ÀúÇ÷¾ÐÀ̶ó°í ÇÑ´Ù. ±×·¯³ª °íÇ÷¾ÐÁõÀÇ »ç¶÷ÀÌ ±Þ°ÝÈ÷ Ç÷¾ÐÀÌ ¶³¾îÁø °æ¿ì´Â Ç÷¾ÐÄ¡°¡ ºñ·Ï Á¤»ó ¹üÀ§¶ó ÇÒÁö¶óµµ ÀúÇ÷¾Ð Áõ¼¼¸¦ ÃÊ·¡ÇÏ´Â ¼ö°¡ ÀÖ´Ù. ÀúÇ÷¾ÐÀ» ÃÊ·¡ÇÏ´Â ÁúȯÀ¸·Î¼­´Â Å©°Ô ¸¸¼º Áö¼Ó¼º ÀúÇ÷¾ÐÁõ°ú ±â¸³¼º ÀúÇ÷¾Ð ¹× ¼îÅ©°¡ ÀÖ´Ù.¡¼¸¸¼º Áö¼Ó¼º ÀúÇ÷¾ÐÁõ¡½ °¢Á¾ÀÇ ½É Áúȯ
  • low-voltage low-amperage biphasic current
    ÀúÀü¾Ð ÀúÀü·ùÀÇ º¹Çü Àü·ù
  • low-voltage, low-amperage, biphasic current
    ÀúÀü¾Ð ÀúÀü·ùÀÇ º¹Çü Àü·ù
  • accelerated hypertension
    °¡¼Ó¼º °íÇ÷¾Ð
  • essential hypertension
    º»Å¼º °íÇ÷¾Ð
    1. Ưº°ÇÑ ¿øÀÎÀÌ ¾Ë·ÁÁöÁö ¾ÊÀº °íÇ÷¾ÐÀ» ÀǹÌÇϸç ÀÌ´Â Àüü °íÇ÷¾Ð ȯÀÚÀÇ 85-90£¥¸¦ Â÷ÁöÇÑ´Ù. 2. À¯Àü, Á¤½ÅÀû ½ºÆ®·¹½º, ¿°ºÐÀÇ Áõ°¡ µî Ç÷¾Ð »ó½ÂÀÌ º¹ÇÕÀûÀÎ ¿øÀÎ ÇüÅ·Π³ªÅ¸³­´Ù.
  • hypertension paroxystique
    ºÒ ¹ßÀÛ¼º °íÇ÷¾Ð
  • juvenile hypertension
    ¿¬¼Ò¼º °íÇ÷¾ÐÁõ, ¿¬¼Ò¼º °íÇ÷¾Ð
  • labile hypertension
    ºÒ¾ÈÁ¤¼º °íÇ÷¾Ð
  • nephrogenous hypertension
    ½Å¼º °íÇ÷¾Ð
  • ocular hypertension indicator
    ¾È±¸ °íÇ÷¾Ð ÁöÇ¥
  • orthostatic hypertension
    ±â¸³¼º °íÇ÷¾Ð, ÀÚ¼¼¼º °íÇ÷¾Ð
  • portal hypertension
    ¹®¸Æ¼º °íÇ÷¾Ð, °£¹®¸Æ °íÇ÷¾Ð, ¹®¸Æ¾Ð Ç×ÁøÁõ, ¹®¸Æ °íÇ÷¾Ð
  • primary hypertension
    ¿ø¹ß °íÇ÷¾ÐÁõ, ¿ø¹ß¼º °íÇ÷¾ÐÁõ
  • pulmonary arterial hypertension
    Æó ¼øÈ¯ ½Â¾Ð
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
renin <enzyme> An enzyme of the hydrolase class that catalyses cleavage of the leucine leucine bond in angiotensin to generate angiotensin. 1.
The enzyme is synthesised as inactive prorenin in the kidney and released into the blood in the active form in response to various metabolic stimuli. Not to be confused with rennin (chymosin).
(25 Jun 1999)
renin-angiotensin-aldosterone system The hormones, renin, angiotensin, and aldosterone work together to regulate blood pressure. A sustained fall in blood pressure causes the kidney to release renin. This is converted to angiotensin in the circulation. Angiotensin then raises blood pressure directly by arteriolar constriction and stimulates adrenal gland to produce aldosterone which promotes sodium and water retention by kidney, such that blood volume and blood pressure increase.
(05 Mar 2000)
renin-angiotensin system <physiology> A system consisting of renin, angiotensin-converting enzyme, and angiotensin II.
Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming angiotensin I. The converting enzyme contained in the lung acts on angiotensin I in the plasma converting it to angiotensin II, the most powerful directly pressor substance known. It causes contraction of the arteriolar smooth muscle and has other indirect actions mediated through the adrenal cortex.
(25 Jun 1999)
plasma renin activity The estimation of renin in plasma by measuring the rate of formation of angiotensin I or II.
(05 Mar 2000)
accelerated hypertension <cardiology> A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
adrenal hypertension Hypertension due to an adrenal medullary pheochromocytoma or to hyperactivity or functioning tumour of the adrenal cortex.
(05 Mar 2000)
benign hypertension Hypertension that runs a relatively long and symptomless course.
(05 Mar 2000)
borderline hypertension By consensus, that blood pressure zone between highest acceptable "normal" blood pressure and hypertensive blood pressure. The Framingham Heart Study defines this as pressures between 140 and 160 mm Hg systolic and 90 and 95 mm Hg diastolic.
(05 Mar 2000)
pale hypertension Hypertension with pallor of the skin, a severe form with pronounced constriction of peripheral vessels.
(05 Mar 2000)
malignant hypertension A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
renal hypertension Hypertension secondary to renal disease.
(05 Mar 2000)
renovascular hypertension Hypertension produced by renal arterial obstruction.
(05 Mar 2000)
Goldblatt hypertension Increased blood pressure following obstruction of blood flow to one kidney.
Synonym: Goldblatt phenomenon.
(05 Mar 2000)
portal hypertension Any increase in the portal vein (in the liver) pressure due to anatomic or functional obstruction (for example alcoholic cirrhosis) to blood flow in the portal venous system. Indicators of portal hypertension are: oesophageal varices, haemorrhoids, enlarged veins on the anterior abdominal wall (caput Medusae) and ascites (fluid within the abdominal cavity).
(27 Sep 1997)
portal hypertension: classification <radiology> Presinusoidal, extrahepatic: portal vein obstruction (extrinsic compression, phlebitis, OC, coagulopathy, tumour invasion, pancreatitis, neonatal omphalitis), dynamic: traumatic/neoplastic arterioportal fistula, segmental portal hypertension: splenic/superior mesenteric vein occlusion, intrahepatic (obstruction of portal venules): congenital hepatic fibrosis, primary biliary cirrhosis, sarcoid, myelofibrosis, schistosomiasis, idiopathic noncirrhotic fibrosis, Wilson disease, reticuloendotheliosis, Felty syndrome, chronic malaria, toxic fibrosis (arsenic, copper, PVC vapors) sinusoidal, cirrhosis, sclerosing cholangitis postsinusoidal, Budd-Chiari syndrome, constrictive pericarditis, congestive heart failure
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • renin
    ·¹´Ñ(½ÅÀå ³»¿¡¼­ »ý±â´Â ´Ü¹éÁú ºÐÇØ È¿¼Ò)
  • hypertension
    °íÇ÷¾Ð; °úµµ ±äÀå
  • hypertension
    °íÇ÷¾Ð
  • low
    ³·Àº,³·°Ô,õÇϰÔ,(¼Ò°¡)¿ï´Ù
  • low-minded
    ºñ¿­ÇÑ
  • Low Church
    Àú±³È¸ÆÄ(¿µ±¹ ±¹±³ÆÄÁß,±³È¸ÀÇ ±³¸®,ÀǽĿ¡ ÁßÁ¡À» µÎÁö ¾Ê´Â ÇÑ ÆÄ)
  • Low Churchman
    Àú±³È¸ÆÄÀÇ »ç¶÷
  • Low Countries
    Áö±ÝÀÇ BeneluxÀÇ ÃÑĪ
  • Low Mass
    Æò¹Ì»ç
  • Low Sunday
    ºÎȰÀý ´ÙÀ½ÀÇ ÀÏ¿äÀÏ
  • Middle Low German
    Áß¼¼(Áß±â) ÀúÁö µ¶ÀϾî(12-15¼¼±â)
  • low
    ³·Àº;ÀúÁöÀÇ;Àú±ÞÇÑ;ħ¿ïÇÑ;°ª½Ñ;ÀûÀº;°Ë¼ÒÇÑ;ÀúÁ¶ÀÇ;ÀúÀ½ÀÇ;be in ~ water µ·¿¡ ±ÃÇÏ´Ù;bring ~ ¼èÅðÄÉ ÇÏ´Ù;ÁÙÀÌ´Ù
  • low
    ³·°Ô;³·Àº °÷¿¡;¾ßºñ(õ)ÇϰÔ;½Î°Ô;°Ë¼ÒÇÑ À½½ÄÀ¸·Î;Àûµµ °¡±îÀÌ;~ down ÈξÀ ¾Æ·¡¿¡;Ǫ´ëÁ¢ÇÏ¿©
  • low
    ³·Àº °Í;Àú¼Ó±â¾î;Àú±â¾Ð
  • low
    ¼ÒÀÇ ¿ïÀ½¼Ò¸®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á